Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion proteinRBD-뉴클레오캡시드 융합단백질을 이용한 관심대상 야생형 및 SARS-CoV-2 변이체에 대한 중화항체 비의존성 면역 촉진Article Published on 2022-08-172022-09-11 Journal: Nature Communications [Category] SARS, 변종, 임상, 진단, 치료기술, 치료법, [키워드] ablated angiotensin antibody Antigen B cell B cells Blood CD4 CD8 chimeric circumvent Clinical outcome convertase COVID-19 convalescent donors COVID-19 vaccine COVID-19 vaccines Delta Depletion detectable effector T cell effector T cells elicit elicited experimental model experimental models fusion protein generate hamster IFN-γ Immune escape Immunity immunization IMPROVE inactivated indicated individual Infection infection with SARS-CoV-2 less lethality levels of antibody Lung inflammation mice NAbs Neutralizing Neutralizing antibodies neutralizing antibody nucleocapsid omicron promote promotion PROTECT Protein protocol protocols RBD RBD protein Receptor binding domain reduction robust SARS-CoV-2 SARS-CoV-2 isolates SARS-CoV-2 vaccine SARS-CoV-2 variant shown spike Spin T cell T cells transferred vaccination Vaccine variants variants of concern Viral Viral load virus wild type wild-type [DOI] 10.1038/s41467-022-32547-y PMC 바로가기 [Article Type] Article
Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variantsSARS-CoV-2 변이체에 대한 살균 면역을 유도할 수 있는 접힌 수용체 결합 도메인-PreS 융합 단백질 기반 백신Article Published on 2022-08-012022-09-11 Journal: Allergy [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus antibody Antibody Response Antigen C-terminus carrier cellular combination vaccine construction convalescent coronavirus COVID-19 COVID-19 pandemic fused fusion protein Genetic genotypes HBV healthy subject healthy subjects hepatitis B Hepatitis B virus human cell human cells IgG IgG antibodies IgG antibody IgG response Immunity immunized in vitro in vivo induce inhibited Interaction maintenance median mucosal secretions Neutralizing Neutralizing antibodies neutralizing antibody neutralizing titers Omicron variant pandemic Protein random Random sample RBD RBD-specific IgG RBD-specific IgG response receptor ACE2 Receptor binding Receptor-binding domain recombinant fusion protein Registered replicate respiratory response responsible robust SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants serum severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 specific antibodies specific IgG antibodies spike Spike protein sterilizing immunity subject subjects subunit Subunit vaccine surface antigen sustained Vaccine Viral viral replication virus entry virus-neutralizing VNT [DOI] 10.1111/all.15305 PMC 바로가기 [Article Type] Article
Guanine nucleotide exchange factor DOCK11-binding peptide fused with a single chain antibody inhibits hepatitis B virus infection and replicationArticle Published on 2022-07-012023-06-13 Journal: The Journal of Biological Chemistry [Category] B형 간염, [키워드] anti-HBV peptide drug antibody engineering DOCK11 drug delivery fusion protein Hepatitis B virus IVV method peptide drug delivery peptide transport. [DOI] 10.1016/j.jbc.2022.102097 PMC 바로가기
Antibody-Invertase Fusion Protein Enables Quantitative Detection of SARS-CoV-2 Antibodies Using Widely Available Glucometers항체-인버타제 융합 단백질은 널리 사용되는 혈당계를 사용하여 SARS-CoV-2 항체의 정량적 검출을 가능하게 합니다Article Published on 2022-06-292022-09-11 Journal: Journal of the American Chemical Society [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료제, [키워드] anti-SARS-CoV-2 antibodies antibody Antigen antigens bind binding binding affinity blinded Care catalytic catalytic activity coupling COVID-19 pandemic Critical detect detection diagnostics disease outbreaks disease risk effective Efficiency equipment facilitate fused fusion fusion protein Glucose IgG IgG isotypes immunoassays Immunoglobulin Immunoglobulin G Infectious disease Outbreaks overcome Patient proportion Protein Quantitative Rapid reduced reporter resulting SARS-CoV-2 SARS-CoV-2-specific IgG SARS-CoV-2-specific IgGs secondary antibodies secondary antibody serology assay serum specific antibodies Spike protein Spread the binding affinity the patient training sets [DOI] 10.1021/jacs.2c02537 PMC 바로가기 [Article Type] Article
IgG targeting distinct seasonal coronavirus- conserved SARS-CoV-2 spike subdomains correlates with differential COVID-19 disease outcomes뚜렷한 계절성 코로나바이러스-보존 SARS-CoV-2 스파이크 하위 도메인을 표적으로 하는 IgG는 차별적인 COVID-19 질병 결과와 상관관계가 있습니다Article Published on 2022-05-312022-09-11 Journal: Cell Reports [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료제, [키워드] Activation ADE amplification anti-Spike IgG anti-spike IgG levels anti-spike IgG response Anti-spike IgG responses antibody antibody-mediated effector responses Betacoronavirus betacoronaviruses caused conserved convalescent individual coronavirus COVID-19 COVID-19 disease COVID-19 patient COVID-19 severity CoVs CP: Immunology CP: Microbiology cross-reactivity Deleterious disease disease severity Early detection epitope Epitopes Fc-gamma receptor activation FcγR fusion protein fusion protein region greater heptad repeat heptad repeat region human betacoronavirus human betacoronavirus. humoral IgG IgG responses immunodominant epitope immunology lowest memory response Microbiology observé OC43 offer outcome predict profile Protective recall receptor responses SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 spike protein SARS1 seasonal coronaviruses severe COVID-19 patient severe COVID-19 patients severe disease significantly Spectrum Spike protein the SARS-CoV-2 virus β-CoVs [DOI] 10.1016/j.celrep.2022.110904 PMC 바로가기 [Article Type] Article
Targeting the Interaction Between Spike Protein and Nucleocapsid Protein for Suppression and Detection of Human Coronavirus OC43인간 코로나바이러스 OC43의 억제 및 검출을 위한 스파이크 단백질과 뉴클레오캡시드 단백질 간의 상호작용 표적화Article Published on 2022-03-102022-09-11 Journal: Frontiers in Immunology [Category] SARS, 변종, 치료기술, 치료법, 치료제, [키워드] anti-HCoV-OC43 anti-HCoV-OC43 N antibody bait and prey C-terminal domain Cell colds conserved coronavirus detect detection ELISA fusion protein HCoV HCoV-OC43 Human human coronavirus human coronavirus OC43 in vitro Infection inhibit interact Interaction investigated MERS MERS-CoV monoclonal antibody N protein N proteins Novel coronavirus nucleocapsid nucleocapsid protein OC43 Penetrating peptide prey producing Protein protein expression Replication replication of SARS-CoV-2 reported S protein SARS-CoV-2 spike Spike protein suppression target targeting the S protein Therapeutics upper respiratory tract variants virus virus detection [DOI] 10.3389/fimmu.2022.835333 PMC 바로가기 [Article Type] Article
Nanobody-Functionalized Cellulose for Capturing SARS-CoV-2SARS-CoV-2 포획을 위한 나노바디 기능화 셀룰로오스Article Published on 2022-03-082022-09-11 Journal: Applied and Environmental Microbiology [Category] SARS, 변종, 치료기술, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Bacteria binding biological fluid Blood Cellulose cellulose binding domain cellulose binding protein complement complementary complex coronavirus COVID-19 COVID-19 pandemic cytokine Cytokines D614G variant diagnostics domain Efficiency effort exhibited filtration fluids fungi fusion protein help higher infectivity immobilization IMPROVE infected individuals intrinsic lockdowns mandatory mitigate nanobody porous preventative measures proof proof of concept provided pseudoviruses Receptor-binding domain reducing removal SARS-CoV-2 SARS-CoV-2 pseudovirus SARS-CoV-2 pseudoviruses sensitivities shown substrate the receptor-binding domain Therapeutic strategies utility vaccination Vaccinations Viral detection Viral load viral spread Viral transmission virus viruses wild type [DOI] 10.1128/aem.02303-21 PMC 바로가기 [Article Type] Article
ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concernACE2-Fc 융합 단백질은 우려되는 SARS-CoV-2 변이체를 강력하게 중화하여 바이러스 탈출을 극복합니다Article Published on 2022-03-012022-09-11 Journal: Antiviral Research [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 진단, [키워드] ACE2-Fc Analysis antibodies Antibody drugs approved binding Biotechnology breakthrough infections caused Clinical data Comprehensive COVID-19 dominant variant drug drug design drug resistance Efficiency EMA experiment FDA fusion protein Glycoproteins increasingly Infectious disease Interaction mechanism monoclonal antibodies monoclonal antibody Mutation neutralization neutralize Neutralizing not compromised omicron overcome Protein binding Proteins public health remained SARS-CoV-2 variant SARS-CoV-2 virus spike variants tested the SARS-CoV-2 virus therapeutic therapeutic agent therapeutic antibodies Therapeutic antibody treat Treatment vaccinated individual vaccinated individuals Vaccine variant variants Viral viral escape viral infection [DOI] 10.1016/j.antiviral.2022.105271 PMC 바로가기 [Article Type] Article
Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452IgG-Fc 융합 COVID-19 서브유닛 백신 AKS-452에 대한 I/II상 연구의 I상 중간 결과Clinical Trial Published on 2022-02-232022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 AKS-452 Alpha alpha and delta variants anti-SARS-CoV-2 Antigen caused Cell Cohort cohorts cold chain complex conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Delta variants distribution dose Endpoint Fc-fusion fusion protein healthy human IgG1 Fc IgG titer IgG titers immunogenicity assessments Infection Infectious disease Live virus mutant neutralization potency occurred Open-label pandemic phase Phase I primary endpoints profile Prophylaxis reactogenicity receiving Receptor binding domain respiratory SAE SAEs SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 viral infection secondary endpoint Secondary endpoints seroconversion rates severe acute respiratory syndrome Coronavirus single-center Single-dose skewed Spike protein subject subunit Subunit vaccine Support the SARS-CoV-2 vaccination Vaccine Viral viral infections viral spike protein virus infection [DOI] 10.1016/j.vaccine.2022.01.043 PMC 바로가기 [Article Type] Clinical Trial
Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative ReviewReview Published on 2022-02-152022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] activating acute respiratory syndrome Affect antibody appear attenuate B-cell biologic Biologic therapy coronavirus CTLA-4 described dose Efficacy evaluated fusion protein healthy individuals IL-17 IL-6 immune response immune system Immune-mediated inflammatory disease Immune-mediated inflammatory diseases immunosuppressants immunosuppressive immunosuppressive drugs impair increased risk Infection Inflammatory bowel disease inhibitor inhibitors integrin Interleukins knowledge limit Live attenuated vaccine narrative Necrosis pathogenic Patient patients patients receiving treatment patients treated protective immune response protective response recommendation reduced replicate response responses review rheumatoid arthritis risk of infection Safe SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine severe disease Therapies therapy TNF treat Treatment vaccination Vaccine vaccine response Vaccines [DOI] 10.3390/vaccines10020297 PMC 바로가기 [Article Type] Review